MG98: BBG said MOGN started Phase I studies of continuous 2 week infusions of MG98 in undisclosed number of patients. BBG has European rights to MG98 under a Fe

British Biotech plc (LSE:BBG; BBIOY), Oxford, U.K. MethylGene Inc., Montreal, Quebec MGI Pharma Inc. (MOGN), Minneapolis, Minn. Product: MG98 Business: Cancer Therapeutic category: Antisense Target:...